Compare DexCom, Inc. (DXCM) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Huntington Bancshares Incorporated — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while Huntington Bancshares Incorporated trades at $17.77 (market cap $35.93B). The key difference: DexCom, Inc. and Huntington Bancshares Incorporated are close in size by market cap, and Huntington Bancshares Incorporated pays a 3.49% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | HBAN | |
|---|---|---|
Market Cap | $33.79B | $35.93B |
Sector | Health | Financials |
52-Week High | $89.53 | $19.27 |
52-Week Low | $54.84 | $15.02 |
Enterprise Value | $33.24B | — |
Dividend Yield | — | 3.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
HBAN trades at $17.85, up 1.42% today, with a bullish technical signal from moving averages and a consensus price target of $19.78. Recent Q2 2026 earnings matched estimates, with revenue growth and net interest income rising year-over-year. The company targets an 18-19% ROTCE by 2027, supported by efficiency gains and capital returns. However, rising deposit costs and mixed quarterly EPS results present near-term challenges.
The outlook for HBAN is cautiously optimistic, with potential upside from strategic growth initiatives and a reasonable P/E of 13.68. Risks include margin pressure from higher funding costs and volatile earnings performance. Analyst sentiment is balanced, with 44.68% buy ratings, but investors should monitor expense management and loan growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
